Home > Newsletters > FDAnews Drug Daily Bulletin > Boehringer Ingelheim Completes Enrollment of Pivotal Phase III Studies for Nintedanib in Idiopathic Pulmonary Fibrosis
FDAnews Drug Daily Bulletin
Sept. 28, 2012 | Vol. 9 No. 191
Boehringer Ingelheim Completes Enrollment of Pivotal Phase III Studies for Nintedanib in Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim announced that clinical trial enrollment has completed for two Phase III studies evaluating the safety and efficacy of nintedanib (BIBF 1120), an investigational compound, in patients with idiopathic pulmonary fibrosis, being studied at a twice-daily oral dose.
The Sacramento Bee
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.